C14orf143 Activators
C14orf143 (EF-hand calcium binding domain 11) activators function through a variety of mechanisms to enhance the protein's activity by influencing intracellular calcium levels and cAMP-dependent pathways. Certain activators exert their effects by directly increasing the concentration of intracellular calcium, which binds to the EF-hand domain of C14orf143, thus enhancing its function. This is achieved through either the transportation of calcium across cellular membranes or by modulating intracellular stores of calcium. These changes in calcium dynamics ensure the optimal activation of C14orf143, as its activity is closely tied to its ability to bind calcium ions. Other activators indirectly influence the protein's activity by targeting signaling pathways that lead to phosphorylation events. By increasing levels of cAMP, they activate protein kinase A (PKA) or protein kinase C (PKC). The subsequent phosphorylation of proteins within these pathways can modify the interaction between C14orf143 and calcium, thereby modulating the protein's calcium-binding affinity and enhancing its overall activity.
Moreover, some activators work by inhibiting the breakdown of cAMP, thereby sustaining the activity of kinases that are known to phosphorylate proteins and influence their function. This indirect route of activation involves maintaining higher levels of cAMP, leading to prolonged kinase activity and potential phosphorylation of C14orf143. Additionally, certain compounds can stimulate adenylyl cyclase or act as beta-adrenergic agonists, elevating cAMP levels, and leading to enhanced PKA activity. The phosphorylation mediated by these kinases can alter the EF-hand calcium-binding domain of C14orf143, increasing its capacity to bind calcium and, consequently, its activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Increases intracellular calcium concentration by forming complexes with calcium ions. The elevated calcium levels directly activate C14orf143 by binding to its calcium-binding EF-hand domain, enhancing its function. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 5 g 100 g 250 g 1 kg 5 kg | $32.00 $66.00 $95.00 $188.00 $760.00 | 13 | |
Phosphodiesterase inhibitor that prevents the breakdown of cAMP, indirectly increasing PKA activity which can lead to the phosphorylation of C14orf143, thus enhancing its calcium binding capacity and activity. | ||||||
8-Bromo-cAMP | 76939-46-3 | sc-201564 sc-201564A | 10 mg 50 mg | $97.00 $224.00 | 30 | |
Analog of cAMP that is resistant to degradation by phosphodiesterases, leading to sustained PKA activation. PKA then potentially phosphorylates C14orf143, increasing its activity through enhanced calcium binding. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
Ionophore that transports calcium ions across cellular membranes, increasing intracellular calcium concentration. This directly activates C14orf143 by promoting calcium ion binding to its EF-hand domain. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Inhibits the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA), causing a rise in cytosolic calcium levels which directly activates C14orf143 by binding to the EF-hand domain. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Activates protein kinase C (PKC) which can lead to downstream phosphorylation events. Phosphorylation of proteins can enhance the functional activity of C14orf143 by modifying its interaction with calcium ions. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $27.00 $37.00 | 5 | |
Beta-adrenergic agonist that stimulates adenylyl cyclase to produce cAMP, indirectly activating PKA. PKA can then phosphorylate C14orf143, modulating its EF-hand calcium-binding domain and activity. | ||||||
(±)-Bay K 8644 | 71145-03-4 | sc-203324 sc-203324A sc-203324B | 1 mg 5 mg 50 mg | $82.00 $192.00 $801.00 | ||
L-type calcium channel agonist that increases calcium influx, directly increasing the calcium concentration available for binding to C14orf143, thereby activating it. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $90.00 $371.00 | 2 | |
Beta2-adrenergic agonist that elevates intracellular cAMP, leading to PKA activation. PKA can phosphorylate C14orf143, enhancing its calcium-binding capability and functional activity. | ||||||
Ryanodine | 15662-33-6 | sc-201523 sc-201523A | 1 mg 5 mg | $219.00 $765.00 | 19 | |
Modulates the ryanodine receptor which regulates calcium release from sarcoplasmic reticulum, increasing intracellular calcium levels. This directly activates C14orf143 through increased calcium binding to the EF-hand domain. | ||||||